Table 1:
N = 50 | |
---|---|
Age | 48 (18 - 64) |
Race | |
White | 30 / 50 (60%) |
Black | 10 / 50 (20%) |
Asian | 2 / 50 (4.0%) |
Hispanic | 1 / 50 (2.0%) |
Other | 7 / 50 (14%) |
Gender | |
Female | 22 / 50 (44%) |
Male | 28 / 50 (56%) |
Diagnosis | |
AML | 45 / 50 (90%) |
MDS | 4 / 50 (8.0%) |
MPAL | 1 / 50 (2.0%) |
Cytogenetic Group | |
Favorable | 1 / 50 (2.0%) |
Diploid | 25 / 50 (50%) |
Other Intermediate | 8 / 50 (16%) |
Adverse/Complex | 10 / 50 (20%) |
Insufficient Mitoses | 5 / 50 (10%) |
ELN Risk | |
Favorable | 16 / 46 (35%) |
Intermediate | 14 / 46 (30%) |
Adverse | 16 / 46 (35%) |
IPSS-R | |
High | 2 / 4 (50%) |
Very High | 2 / 4 (50%) |
Baseline Bone
Marrow Blasts |
|
AML | 59 (1 – 84) |
MDS | 9.5 (8-18) |
MPAL | 82 |
Baseline WBC | 6 (1 - 70) |
Baseline Peripheral Blasts | 20 (1 - 95) |
Baseline Hemoglobin | 8.60 (7.00 - 13.20) |
Baseline Platelet Count | 44 (6 - 398) |
Baseline Total Bilirubin | 0.40 (0.20 - 1.30) |
Baseline Serum Creatinine | 0.84 (0.50 - 1.39) |
Median (Range); n / N (%)